Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with
terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI